The Effectiveness of Supplementing Supported Employment With Behavioral Skills Training
Overview
- Phase
- Phase 4
- Intervention
- Individual Placement and Support (Supported Employment)
- Conditions
- Schizophrenia
- Sponsor
- University of California, Los Angeles
- Enrollment
- 107
- Locations
- 2
- Primary Endpoint
- Total Weeks Worked
- Status
- Completed
- Last Updated
- 2 months ago
Overview
Brief Summary
This study will compare employment support with behavioral skills training to employment support alone in schizophrenia patients taking either risperidone or olanzapine to determine which is more effective in helping the patients maintain a job.
Detailed Description
Schizophrenia is a severe mental disorder characterized by disorganized thoughts, difficulty concentrating, and hallucinations. Individuals with schizophrenia often experience reduced emotional, social, and occupational functioning. Data indicate that antipsychotic drug treatment and occupational training and support may be effective in helping people with schizophrenia maintain a stable job. Risperidone and olanzapine are antipsychotic drugs; participants in this study will be taking either risperidone or olanzapine for the duration of the study. This study will provide schizophrenia patients with employment support alone or with behavioral skills training to determine which combination is more effective in helping patients obtain and maintain a job. At study entry, participants will undergo a clinical and diagnostic evaluation to determine the severity of their schizophrenia. Participants will be tapered off their regular medication for schizophrenia over 4 weeks. At the end of Week 4, they will be randomly assigned to receive either risperidone or olanzapine. Participants will then be assigned an Individual Placement and Support (IPS) specialist to assist them in finding a job. After participants secure a job, they will be randomly assigned to receive IPS either alone or with the Workplace Fundamentals Skills Training Module for 2 years. Participants' risperidone or olanzapine treatment will continue during this 2-year period. Participants will have clinic visits at study entry and Months 7, 12, and 24. At each visit, participants will complete questionnaires and will be interviewed about their schizophrenia symptoms and occupational functioning.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of schizophrenia
- •Candidate for maintenance schizophrenia treatment
- •Willing to initiate and continue risperidone or olanzapine therapy for the duration of the study
Exclusion Criteria
- •Any serious medical problems other than schizophrenia that would interfere with the study
Arms & Interventions
Risperidone Plus Supported Employment
Intervention: Individual Placement and Support (Supported Employment)
Risperidone Plus Supported Employment
Intervention: Risperidone
Olanzapine Plus Supported Employment
Intervention: Individual Placement and Support (Supported Employment)
Olanzapine Plus Supported Employment
Intervention: Olanzapine
Risperidone+Supported Employment+Skills
Intervention: Individual Placement and Support (Supported Employment)
Risperidone+Supported Employment+Skills
Intervention: Social Skills Training
Risperidone+Supported Employment+Skills
Intervention: Risperidone
Olanzapine+Supported Employment+Skills
Intervention: Individual Placement and Support (Supported Employment)
Olanzapine+Supported Employment+Skills
Intervention: Social Skills Training
Olanzapine+Supported Employment+Skills
Intervention: Olanzapine
Outcomes
Primary Outcomes
Total Weeks Worked
Time Frame: 24 months
Secondary Outcomes
- Body Mass Index(First 18 months of study)